Lyell Immunopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	90.77	60.18	105.6	145.65	123.55	293.83
Short-Term Investments	163.25	187.04	264.93	400.58	516.6	320.97
Cash & Short-Term Investments	254.02	247.22	370.53	546.22	640.15	614.79
Cash Growth	-15.66%	-33.28%	-32.17%	-14.67%	4.13%	0.36%
Other Current Assets	13.28	13.72	9.07	8.46	11.14	11.49
Total Current Assets	267.3	260.94	379.59	554.69	651.3	626.29
Net Property, Plant & Equipment	50.55	53.64	72.94	142.32	166.27	166.64
Long-Term Investments	25.95	19	32.01	48.51	115.04	330.53
Other Long-Term Assets	6.82	6.47	6.31	4.52	4.96	3.95
Total Assets	350.63	340.05	490.86	750.03	937.56	1,127
Accounts Payable	5.47	2.89	5.37	4.82	3.92	3.21
Accrued Expenses	31.48	46.52	40.82	28.13	28.76	29.06
Unearned Revenue	-	-	-	-	-	4.99
Other Current Liabilities	-	-	7.6	1.58	4.36	9.49
Total Current Liabilities	36.95	49.41	53.79	34.52	37.03	46.74
Long-Term Leases	39.49	41.92	50.99	56.89	63.17	66.65
Other Long-Term Liabilities	0.53	0.52	3.25	3.66	4.11	84.23
Total Long-Term Liabilities	40.01	42.44	54.25	60.56	67.28	150.88
Total Liabilities	76.96	91.85	108.04	95.08	104.31	197.62
Common Stock	0	0	0	0.03	0.03	0.02
Additional Paid-in Capital	1,917	1,868	1,728	1,657	1,608	1,516
Accumulated Other Comprehensive Income	-0.01	0.24	0.29	-0.09	-7.6	-1.62
Retained Earnings	-1,644	-1,620	-1,345	-1,002	-767.48	-584.36
Total Common Shareholders' Equity	273.67	248.2	382.82	654.95	833.25	929.79
Shareholders' Equity	273.67	248.2	382.82	654.95	833.25	929.79
Total Liabilities & Equity	350.63	340.05	490.86	750.03	937.56	1,127
Total Debt	39.49	41.92	50.99	56.89	63.17	66.65
Net Cash (Debt)	214.54	205.3	319.53	489.33	576.98	548.14
Net Cash Growth	4.50%	-35.75%	-34.70%	-15.19%	5.26%	-2.41%
Net Cash Per Share	11.37	12.01	24.44	38.99	46.70	80.66
Book Value	273.67	248.2	382.82	654.95	833.25	929.79
Book Value Per Share	14.51	14.52	29.28	52.19	67.45	136.82
Tangible Book Value	273.67	248.2	382.82	654.95	833.25	929.79
Tangible Book Value Per Share	14.51	14.52	29.28	52.19	67.45	136.82

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q